文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-DOTA-Pentixafor PET/CT 在良性功能性肾上腺皮质病变中的诊断效能

Diagnostic Performance of 68 Ga DOTA-Pentixafor PET/CT in Benign Functional Adrenal Cortical Lesions.
PubMed 文献 · Clin Nucl Med · 2026-03-24

结果显示病灶局灶性摄取在疑似PA者中为6/6(100%),疑似CS者中为5/18(27.7%),疑似EAS者中为1/1(100%);手术证实的PA和CS均为肾上腺皮质腺瘤,无假阳性,但因2例CS假阴性,总体灵敏度83.3%、特异度100%、准确率85.7%。

要点

  • 68Ga-DOTA-Pentixafor PET/CT对功能性肾上腺皮质病变具有高特异度(100%)和较高准确率(85.7%)。
  • 疑似PA患者中局灶性摄取比例为6/6(100%),疑似CS患者中为5/18(27.7%)。
  • 手术证实的PA和CS患者术后临床及生化改善比例均为100%(5/5)。

核心结论

  • 68Ga-DOTA-Pentixafor PET/CT是良性功能性肾上腺皮质病变(如PA、CS、EAS)的有价值诊断工具,并可能成为微创患者管理的新标准。

研究设计与样本

  • 分析病灶SUVmax、LCRSUVmax和LLRSUVmax,并与实验室参数、其他影像 modality 及术后临床病理结果进行相关性分析。

主要发现

  • 68Ga-DOTA-Pentixafor PET/CT在疑似PA患者中显示局灶性摄取6/6(100%),疑似CS患者中5/18(27.7%),疑似EAS患者中1/1(100%)。
  • 在局灶性摄取且接受手术的患者中,PA(5/5)和CS(5/5)均证实为肾上腺皮质腺瘤,无假阳性发现(PPV 100%)。
  • 因2例CS假阴性,Pentixafor PET/CT总体灵敏度83.3%、特异度100%、准确率85.7%。
  • SUVmax >15.11、LCRSUVmax >1.74和LLRSUVmax >4.36的灵敏度分别为33.3%、41.7%和41.7%,同时保持100%特异度。
  • 手术治疗的PA患者(5/5)和CS患者(5/5)临床及生化改善比例均为100%。

关键数值与推荐

  • SUVmax >15.11对应灵敏度33.3%、特异度100%。
  • LCRSUVmax >1.74对应灵敏度41.7%、特异度100%。
  • LLRSUVmax >4.36对应灵敏度41.7%、特异度100%。

临床怎么用

  • 68Ga-DOTA-Pentixafor PET/CT可用于疑似良性功能性肾上腺皮质病变的功能特征评估和侧化定位,高特异度有助于确认肾上腺皮质腺瘤。
  • 对疑似PA患者,该显像可能辅助诊断和治疗计划制定;对疑似CS患者,需注意其局灶性摄取比例较低且存在假阴性可能。

局限性

  • 存在2例CS假阴性,导致总体灵敏度受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This prospective study evaluated the diagnostic performance of 68 Ga DOTA-Pentixafor PET/CT in characterizing the functional properties and lateralization of aldosterone-producing and cortisol-producing adrenal cortical lesions. The contribution of Pentixafor PET/CT to diagnosis and treatment planning was assessed in comparison with CT, MRI, and 18 F-FDG PET/CT. PATIENTS AND METHODS: Twenty-five patients with suspected benign functional adrenal cortical masses were included. All patients underwent whole-body imaging at 1 hour and delayed abdominal imaging at 2 hours following intravenous administration of 18 F-FDG and 68 Ga DOTA-Pentixafor. Lesion SUVmax, LCRSUVmax, and LLRSUVmax values were analyzed and correlated with laboratory parameters, other imaging modalities, and postoperative clinical and pathologic outcomes. RESULTS: 68 Ga DOTA-Pentixafor PET/CT demonstrated distinct focal uptake relative to the contralateral adrenal gland and liver parenchyma in 6/6 (100%) patients with suspected PA, 5/18 (27.7%) with suspected CS, and 1/1 (100%) with suspected EAS. Among patients with focal uptake who underwent surgery, all PA (5/5) and all CS (5/5) cases were confirmed as adrenocortical adenomas, resulting in no false-positive findings (PPV 100%). However, due to 2 false-negative CS cases, pentixafor PET/CT demonstrated an overall sensitivity of 83.3%, specificity of 100%, and accuracy of 85.7%. Thresholds of SUVmax >15.11, LCRSUVmax >1.74, and LLRSUVmax >4.36 yielded sensitivities of 33.3%, 41.7%, and 41.7%, respectively, while maintaining 100% specificity. Clinical and biochemical improvement was observed in 100% (5/5) of operated PA patients and 100% (5/5) of operated CS patients. Follow-up of nonoperated patients is ongoing. CONCLUSION: 68 Ga DOTA-Pentixafor PET/CT is a valuable diagnostic and potentially therapeutic tool for benign functional adrenal cortical disorders such as PA, CS, and EAS, with the potential to establish a new standard in minimally invasive patient management.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Şahin ÖF, Tosunoğlu Z, Şahin R, et al. Diagnostic Performance of 68 Ga DOTA-Pentixafor PET/CT in Benign Functional Adrenal Cortical Lesions. Clin Nucl Med. 2026. PMID: 41941246. doi:10.1097/RLU.0000000000006405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。